Movement Alert｜Eli Lilly Rises 3.1% in Regular Trading, GLP-1 Sector Rallies as Multiple Pipeline Collaborations Provide Catalyst

Market Focus08-18 23:37

On August 18, Eli Lilly rose 3.1% in regular trading, trading at $1,220.49/share, with turnover of $9.18 billion. The stock benefited from a broad rally in obesity drug concept stocks against the overall healthcare sector weakness, combined with multiple pipeline collaboration announcements.

On the news front, Eli Lilly entered a global collaboration and license agreement with OmniAb for a new ion channel drug discovery program, with OmniAb eligible to receive up to $370 million in milestone payments plus tiered royalties on global net sales. Separately, Eli Lilly completed a $10 million upfront payment to AlzeCure Pharma under their Alzheimer's disease Alzstatin collaboration. Meanwhile, the company recently initiated a Phase III clinical trial of Brenipatide, its second GLP-1/GIP dual-agonist, for adult depression in China.

The broader GLP-1 sector rallied against the market trend, with the NYSE Healthcare Index down 0.2% while Eli Lilly outperformed as a sector leader. Analyst consensus maintains an overweight rating with a mean price target of $1,345.58.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160920494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 23:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160920494","market":"us","top_or_hot":-1,"title":"Movement Alert｜Eli Lilly Rises 3.1% in Regular Trading, GLP-1 Sector Rallies as Multiple Pipeline Collaborations Provide Catalyst","media":"Market Focus","content":"<p><p>On August 18, Eli Lilly rose 3.1% in regular trading, trading at $1,220.49/share, with turnover of $9.18 billion. The stock benefited from a broad rally in obesity drug concept stocks against the overall healthcare sector weakness, combined with multiple pipeline collaboration announcements.</p><p>On the news front, Eli Lilly entered a global collaboration and license agreement with OmniAb for a new ion channel drug discovery program, with OmniAb eligible to receive up to $370 million in milestone payments plus tiered royalties on global net sales. Separately, Eli Lilly completed a $10 million upfront payment to AlzeCure Pharma under their Alzheimer's disease Alzstatin collaboration. Meanwhile, the company recently initiated a Phase III clinical trial of Brenipatide, its second GLP-1/GIP dual-agonist, for adult depression in China.</p><p>The broader GLP-1 sector rallied against the market trend, with the NYSE Healthcare Index down 0.2% while Eli Lilly outperformed as a sector leader. Analyst consensus maintains an overweight rating with a mean price target of $1,345.58.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Eli Lilly Rises 3.1% in Regular Trading, GLP-1 Sector Rallies as Multiple Pipeline Collaborations Provide Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Eli Lilly Rises 3.1% in Regular Trading, GLP-1 Sector Rallies as Multiple Pipeline Collaborations Provide Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-18 23:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 18, Eli Lilly rose 3.1% in regular trading, trading at $1,220.49/share, with turnover of $9.18 billion. The stock benefited from a broad rally in obesity drug concept stocks against the overall healthcare sector weakness, combined with multiple pipeline collaboration announcements.</p><p>On the news front, Eli Lilly entered a global collaboration and license agreement with OmniAb for a new ion channel drug discovery program, with OmniAb eligible to receive up to $370 million in milestone payments plus tiered royalties on global net sales. Separately, Eli Lilly completed a $10 million upfront payment to AlzeCure Pharma under their Alzheimer's disease Alzstatin collaboration. Meanwhile, the company recently initiated a Phase III clinical trial of Brenipatide, its second GLP-1/GIP dual-agonist, for adult depression in China.</p><p>The broader GLP-1 sector rallied against the market trend, with the NYSE Healthcare Index down 0.2% while Eli Lilly outperformed as a sector leader. Analyst consensus maintains an overweight rating with a mean price target of $1,345.58.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1160920494","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160920494","pubTimestamp":1787067442,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 18, Eli Lilly rose 3.1% in regular trading, trading at $1,220.49/share, with turnover of $9.18 billion. The stock benefited from a broad rally in obesity drug concept stocks against the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"走势警报|礼来公司常规交易上涨3.1%，GLP-1板块反弹，多条管道合作提供催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"On August 18, Eli Lilly rose 3.1% in regular trading, trading at $1,220.49/share, with turnover of $9.18 billion. The stock benefited from a broad rally in obesity drug concept stocks against the overall healthcare sector weakness, combined with multiple pipeline collaboration announcements.On the news front, Eli Lilly entered a global collaboration and license agreement with OmniAb for a new ion channel drug discovery program, with OmniAb eligible to receive up to $370 million in milestone payments plus tiered royalties on global net sales. Separately, Eli Lilly completed a $10 million upfront payment to AlzeCure Pharma under their Alzheimer's disease Alzstatin collaboration. Meanwhile, the company recently initiated a Phase III clinical trial of Brenipatide, its second GLP-1/GIP dual-agonist, for adult depression in China.The broader GLP-1 sector rallied against the market trend, with the NYSE Healthcare Index down 0.2% while Eli Lilly outperformed as a sector leader. Analyst consensus maintains an overweight rating with a mean price target of $1,345.58.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160920494","isCrawlerRequest":true}